Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Mycobacterium avium complex infection: phenotypes and outcomesSource: Eur Respir J, 50 (3) 1701380; 10.1183/13993003.01380-2017 Year: 2017
Clinical relevance of differentiation between Mycobacterium avium and M. intracellulare in M. avium complex pulmonary disease in Croatia Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017
Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa Source: Eur Respir J 2001; 18: Suppl. 33, 480s Year: 2001
The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019 Year: 2020
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009
Invasive Mycobacterium avium intracellulare infection Source: Eur Respir J 2006; 28: Suppl. 50, 312s Year: 2006
Does Mycobacterium bovis appear among the clinical Mycobacterium tuberculosis complex isolates from TB patients of university hospital in Warsaw between 1999 and 2007? Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008
Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017